Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩4,310, the stock trades at a trailing P/E ratio of 22.3x. Average forward P/E is 14x in the Biotechs industry in South Korea. Total loss to shareholders of 48% over the past year. Valuation Update With 7 Day Price Move • Jun 24
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩4,465, the stock trades at a trailing P/E ratio of 23.2x. Average forward P/E is 15x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past year. New Risk • May 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩142.4b (US$94.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩142.4b market cap, or US$94.4m). Valuation Update With 7 Day Price Move • May 29
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩6,020, the stock trades at a trailing P/E ratio of 35.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩6,890, the stock trades at a trailing P/E ratio of 40.3x. Average forward P/E is 22x in the Biotechs industry in South Korea. New Risk • Mar 20
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 69% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to ₩6,510, the stock trades at a trailing P/E ratio of 63.1x. Average trailing P/E is 24x in the Biotechs industry in South Korea. 공고 • Feb 07
GC Genome Corporation, Annual General Meeting, Mar 24, 2026 GC Genome Corporation, Annual General Meeting, Mar 24, 2026, at 14:00 Tokyo Standard Time. Location: conference room, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩7,860, the stock trades at a trailing P/E ratio of 76.1x. Average forward P/E is 19x in the Biotechs industry in South Korea. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩6,490, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 25x in the Biotechs industry in South Korea. 공고 • Dec 09
GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy GC Genome announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in Clinical Chemistry (Impact Factor 6.3, 2025). The findings reveal key physiological factors that can interfere with cancer-associated cfDNA signals, offering a foundation for improving the accuracy of liquid biopsy tests. The study, conducted in collaboration with Professor Min-Jung Kwon and her team at Kangbuk Samsung Medical Center, examined correlations between cfDNA fragmentomic profiles and 65 clinical variables, including age and liver function markers. The goal was to identify potential confounders that could influence cfDNA-based cancer detection in individuals without cancer. Study Overview: Healthy cohort: 1,154 noncancerous individuals who underwent routine health checkups; Clinical variables included: 65 demographic, hematologic, and biochemical parameters; Three fragmentomic features were derived: cfDNA concentration, short-fragment ratio (SFR), and frequency of cancer-enriched motifs (CEMs). Key Findings: Liver enzymes (including AST, ALP, g-GTP) and age were identified as major factors altering cfDNA fragmentation patterns; Elevated AST or age closely resembled cancer-like fragmentomic signatures, blurring the distinction between noncancer and cancer profiles; AST showed high similarity to fragmentation size patterns seen in lung cancer patients (cosine similarity = 0.98). Age showed the similarity to cancer-like profiles among clinical variables (cosine similarity = 0.,52). Receiver Operating Characteristic (ROC) analysis confirmed that these physiological variables can act as founders by reducing the specificity of cfDNA-based detection, potentially leading to false-positive results. These findings demonstrate that non-cancer physiological factors can influence cfDNA signals, underscoring the need for confounder-aware modeling approaches in liquid biopsy development. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩7,200, the stock trades at a trailing P/E ratio of 69.7x. Average trailing P/E is 27x in the Biotechs industry in South Korea. New Risk • Nov 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩147.1b market cap, or US$99.7m). 
